GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » EV-to-EBIT

Glaukos (Glaukos) EV-to-EBIT : -44.19 (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Glaukos's Enterprise Value is $5,581.1 Mil. Glaukos's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-126.3 Mil. Therefore, Glaukos's EV-to-EBIT for today is -44.19.

The historical rank and industry rank for Glaukos's EV-to-EBIT or its related term are showing as below:

GKOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -3262.61   Med: -33.07   Max: 1645.96
Current: -44.19

During the past 11 years, the highest EV-to-EBIT of Glaukos was 1645.96. The lowest was -3262.61. And the median was -33.07.

GKOS's EV-to-EBIT is ranked worse than
100% of 456 companies
in the Medical Devices & Instruments industry
Industry Median: 20.465 vs GKOS: -44.19

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Glaukos's Enterprise Value for the quarter that ended in Mar. 2024 was $4,810.7 Mil. Glaukos's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-126.3 Mil. Glaukos's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.63%.


Glaukos EV-to-EBIT Historical Data

The historical data trend for Glaukos's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos EV-to-EBIT Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.78 -27.68 -57.26 -24.98 -33.25

Glaukos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.79 -31.65 -32.73 -33.25 -38.09

Competitive Comparison of Glaukos's EV-to-EBIT

For the Medical Devices subindustry, Glaukos's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Glaukos's EV-to-EBIT falls into.



Glaukos EV-to-EBIT Calculation

Glaukos's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5581.071/-126.288
=-44.19

Glaukos's current Enterprise Value is $5,581.1 Mil.
Glaukos's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glaukos  (NYSE:GKOS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Glaukos's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-126.288/4810.72963
=-2.63 %

Glaukos's Enterprise Value for the quarter that ended in Mar. 2024 was $4,810.7 Mil.
Glaukos's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glaukos EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Glaukos's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022